Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EPS (Basic): 2016-2025

Historic EPS (Basic) for Summit Therapeutics (SMMT) over the last 5 years, with Sep 2025 value amounting to -$0.31.

  • Summit Therapeutics' EPS (Basic) fell 287.50% to -$0.31 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.25, marking a year-over-year decrease of 420.83%. This contributed to the annual value of -$0.31 for FY2024, which is 68.69% up from last year.
  • Latest data reveals that Summit Therapeutics reported EPS (Basic) of -$0.31 as of Q3 2025, which was up 59.21% from -$0.76 recorded in Q2 2025.
  • Summit Therapeutics' 5-year EPS (Basic) high stood at -$0.01 for Q4 2023, and its period low was -$0.76 during Q2 2025.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.09 (2025), whereas its average is -$0.17.
  • As far as peak fluctuations go, Summit Therapeutics' EPS (Basic) spiked by 75.00% in 2023, and later crashed by 800.00% in 2024.
  • Over the past 4 years, Summit Therapeutics' EPS (Basic) (Quarterly) stood at -$0.04 in 2022, then skyrocketed by 75.00% to -$0.01 in 2023, then plummeted by 800.00% to -$0.09 in 2024, then tumbled by 287.50% to -$0.31 in 2025.
  • Its EPS (Basic) stands at -$0.31 for Q3 2025, versus -$0.76 for Q2 2025 and -$0.09 for Q1 2025.